Status:
COMPLETED
Tranexamic Acid in Cyanotic Heart Defects
Lead Sponsor:
Assiut University
Conditions:
Postoperative Hemorrhage
Eligibility:
All Genders
2-12 years
Phase:
PHASE2
Brief Summary
The use of antifibrinolytic agents such as to reduce blood loss in congenital cardiac surgery has been described in many studies
Detailed Description
40 patients in each one of the three groups; In control group will receive normal saline, Intravenous Tranexamic acid group received 50 mg / kg intravenousely followed by of 1 mg/kg/hr.for six hours. ...
Eligibility Criteria
Inclusion
- 2 to 12 years cyanotic cardiac disease with cardio pulmonary bypass
Exclusion
- Previous cardiac surgery any operation within 48 hr., previous inotropes or mechanical vention aprotinin exposure Liver or renal impairment Coagulation or hemostatic dysfunction within the last 7 days before surgery.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03244423
Start Date
January 1 2009
End Date
August 1 2017
Last Update
January 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Asyut, Egypt, 74111